← All trials
NCT00434291
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2006
- Primary completion
- —
- Completion date
- Aug 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 264
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- TaiGen Biotechnology Co., Ltd.Lead sponsor
- IQVIAOverall official - principal investigator
- University of British ColumbiaOverall official - principal investigator
- Bougainville Hospital, RSAOverall official - principal investigator
- GCT Trial Centre, Mercantile Hospital, RSAOverall official - principal investigator
- National Taiwan UniversityOverall official - principal investigator
- Benmed/Pentagon Hospital, RSAOverall official - principal investigator
- MediTrials, RSAOverall official - principal investigator
- JOSHA Research, RSAOverall official - principal investigator
- Taichung Veterans General HospitalOverall official - principal investigator
- Kaohsiung Medical UniversityOverall official - principal investigator
- Government of TaiwanOverall official - principal investigator
- Tzu Chi UniversityOverall official - principal investigator
- Eastmed Academic Clinical Trial Center, East Lynne, South AfricaOverall official - principal investigator
- Park Medical Center, Witbank, South AfricaOverall official - principal investigator
- IQVIACollaborator
- Changhua Christian HospitalOverall official - principal investigator
- ChengChing HospitalOverall official - principal investigator
- Taipei Veteran General hospitalOverall official - principal investigator
- Chang Gung UniversityOverall official - principal investigator
- I-Shou UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.